AstraZeneca plc (AZN) Price Target Cut to GBX 5,220
AstraZeneca plc (LON:AZN) had its target price trimmed by Bryan, Garnier & Co from GBX 5,400 ($70.49) to GBX 5,220 ($68.14) in a research report sent to investors on Tuesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
AZN has been the subject of several other research reports. Societe Generale reiterated a buy rating and issued a GBX 7,000 ($91.37) target price on shares of AstraZeneca plc in a report on Wednesday, September 14th. Morgan Stanley lifted their target price on shares of AstraZeneca plc from GBX 5,000 ($65.27) to GBX 5,800 ($75.71) and gave the company an overweight rating in a report on Friday, August 19th. Deutsche Bank AG reissued a buy rating and issued a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research report on Wednesday, September 28th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price target on shares of AstraZeneca plc and gave the company a sell rating in a research report on Tuesday, September 6th. Finally, Jefferies Group reissued a buy rating and issued a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research report on Wednesday, September 21st. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5092.5127 on Tuesday. The company has a 50 day moving average price of GBX 5,005.11 and a 200 day moving average price of GBX 4,435.88. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The firm’s market capitalization is GBX 64.42 billion.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. This represents a dividend yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.